INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Aeterna Zentaris Inc. (AEZS) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, notifies investors of the class action lawsuit filed against Aeterna Zentaris Inc. (“Aeterna” or the “Company”) (NASDAQ: AEZS) in the United States District Court for the District of New Jersey.
The complaint allegations focus on whether the Company and its executives violated federal securities laws by making false and misleading statements and/or failing to disclose material facts regarding its business and operations.
On November 6, 2014, Aeterna announced that it had received a Complete Response Letter from the Food and Drug Administration indicating that the New Drug Application for the Company’s drug Macrilen “cannot be approved in its present form.”
Following this news, the price of Aeterna stock declined by $0.64 per share, or nearly 50%, to close on November 6, 2014 at $0.65 per share.
If you invested in Aeterna stock or options prior to November 6, 2014 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Aeterna’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.